The Dermoepidermal Junction as the Initiation Point for Reversal of Dermatoporosis
Abstract
BACKGROUND: Dermatoporosis (DP) or chronic cutaneous fragility syndrome has traditionally been linked to extracellular matrix (ECM) dehydration, reduced cellular turnover, epidermal thinning, and vascular fragility. However, recent imaging methods and clinical evidence indicate that the dermoepidermal junction (DEJ) might be the earliest change reflecting DP reversal. OBJECTIVE: To propose a new mechanistic process in which the DEJ acts as the initiation point for reversing the DP. The process is supported by clinical and imaging evidence, as well as independent literature on DEJ biology. METHODS: A combination of clinical and investigational findings, published theoretical models, and evidence from wound-healing, skin-longevity reports, ex vivo model analyses, and device-based interventions formed the basis for the scientific narrative. RESULTS: Cumulative evidence suggests that an initial change in the DEJ, along with structural restoration, appears to trigger or initiate regenerative processes in the ECM and epidermis. These include the renewal of basal stem cells following adhesion signaling in the basement membrane; ECM remodeling through improved communication between the dermis and epidermis, along with enhanced fibroblast interactions involving collagen and elastin; and finally, ECM remodeling and stabilization of basement membrane anchoring provides support and stability to blood vessels, protecting them from recurrent injury. CONCLUSION: The DEJ acts as a bridge between the epidermis and dermis, providing structural support while also triggering signaling cascades that promote a regenerative environment, contributing to DEJ reversal. Targeting the DEJ could be a logical therapeutic approach, establishing a new paradigm for biomarker analysis and an intervention site for regenerative initiation.  .
- Extracellular matrix remodelling
- Stem cell maintenance
- Extracellular matrix
- Dermatoporosis
- Chronic cutaneous fragility syndrome
- Humans
The paper
Journal of Drugs in Dermatology, 1 Apr 2026



